|
|
Ablation Efficacy and Influencing Factors of Radioactive 131 Iodine in Postoperative Patients with Differentiated Thyroid Cancer |
JIA Yunxiang, HE Xingming, LU Wanjun, et al |
Guangyuan Central Hospital, Sichuan Guangyuan 628000, China |
|
|
Abstract Objective: To explore thyroid ablation efficacy and influencing factors of postoperative radioactive 131 iodine (131I) in patients with differentiated thyroid carcinoma (DTC). Methods: 86 patients with thyroid cancer treated in our hospital from January 2019 to March 2020 were selected and divided into successful and unsuccessful ablation efficacy groups according to the effect of ablation efficacy. The differences of gender, age, pathological type, body mass index, TSH level and STG level before 131I first treatment, primary risk stratification, primary lesion diameter, TNM stage, metastasis and 131I first treatment dose between the two groups were analyzed by single factor statistics, Multivariate logistic regression was used to analyze the influencing factors of 131I nail cleaning efficacy in patients with DTC. Results: Among the 86 patients with DTC, 52 cases had successful ablation efficacy, and the successful rate was 60.47%. Univariate analysis showed that there were significant differences in STG level, recurrence risk stratification, primary lesion diameter and 131I first treatment dose between the successful group and the unsuccessful group (P<0.05); There was no significant difference in gender, age, pathological type, body mass index, TSH level, TNM stage and lymph node metastasis before 131I treatment (P>0.05). Multivariate logistic regression analysis showed that the level of STG before the first treatment of 131I, the diameter of primary lesion and the first treatment dose of 131I were the independent influencing factors of 131I ablation efficacy in patients with DTC (P<0.05). Conclusion: The success rate of thyroid ablation is 60.47% in the 86 patients with DTC. The sTg level before the first 131I treatment, diameter of primary lesions and dosage of the first 131I treatment are independent influencing factors of thyroid ablation efficacy of 131I on DTC patients.
|
|
|
|
|
[1] 贺亮,李蕾蕾,武亚磊,等.经口腔前庭入路腔镜术对单侧甲状腺癌患者美容效果及远期预后的影响[J].中国临床实用医学,2021,12(1):25~28. [2] 谢小红,蔡伟奕,聂芙蓉,等.PCDH8基因甲基化在诊断甲状腺乳头状癌的价值[J].中南医学科学杂志,2020,48(6):96~99,104. [3] Kumar P,Damle N A,Agarwala S,et al.Individualized dosimetry in children and young adults with differentiated thyroid cancer undergoing iodine-131 therapy[J].Pediatr Endocr Met,2020,33(8):1031~1044. [4] 李文亮,杨辉,王森.131I治疗对分化型甲状腺癌患者甲状旁腺素的影响[J].中华内分泌代谢杂志,2021,37(6):554~557. [5] Arjani S,Quinn P L,Chokshi R J.Cost-effectiveness of pre-ablation diagnostic whole-body scan vs empiric radioactive iodine ablation in differentiated thyroid cancer[J].Am Coll Surg,2020,231(4):74~75. [6] 王芳,王越,刁宏翠,等.分化型甲状腺癌术后再次131I治疗前sTg与sTg/sup-Tg对淋巴结转移的预测价值[J].现代肿瘤医学,2020,28(14):2417~2421. [7] 王鑫,宋清斌,徐冬冬,等.术后首次放射性碘治疗时机的选择对分化型甲状腺癌早期疗效的影响[J].中国医科大学学报,2019,48(4):359~362,369. [8] 石磊,王璐,胡德胜,等.分化型甲状腺癌术后131I治疗发生第二原发恶性肿瘤的影响因素的研究进展[J].标记免疫分析与临床,2020,27(4):712~715. [9] 周倩,王瑞华,刘保平,等.高危分化型甲状腺癌手术及131I治疗后疗效分类及影响因素分析[J].中华核医学与分子影像杂志,2021,41(11):664~669. [10] 吴凡.分化型甲状腺癌神经内分泌分化与131I治疗疗效的关系[J].浙江医学,2021,43(14):1518~1521,1536. [11] 白熠洲,郭佳宜,刘安阳,等.中,低危分化型甲状腺癌术后碘(131I)治疗对短期临床转归的影响[J].中国医刊,2019,54(11):1201~1205. [12] 菅雁兵,王冰,苗欣,等.儿童及青少年分化型甲状腺癌的外科治疗及复发影响因素分析[J].解放军医学院学报,2020,41(10):967~970,987. |
|
|
|